These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 18707969)

  • 1. Renin-angiotensin blockade and kidney disease.
    Sarafidis PA; Bakris GL
    Lancet; 2008 Aug; 372(9638):511-2. PubMed ID: 18707969
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.
    Clase CM; Barzilay J; Gao P; Smyth A; Schmieder RE; Tobe S; Teo KK; Yusuf S; Mann JF
    Kidney Int; 2017 Mar; 91(3):683-690. PubMed ID: 27927602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Introduction: Reducing cardiovascular risk: ONTARGET--a new standard in cardiovascular protection.
    Mancia G; Unger T; Zanchetti A
    J Hypertens Suppl; 2009 Jul; 27(5):S1. PubMed ID: 19587549
    [No Abstract]   [Full Text] [Related]  

  • 4. ONTARGET: How much RAS inhibition is enough?
    Weder AB
    Curr Hypertens Rep; 2009 Feb; 11(1):7-9. PubMed ID: 19146793
    [No Abstract]   [Full Text] [Related]  

  • 5. Where does the evidence lead us for the proper use of angiotensin II inhibitors in the management of cardiovascular disease?
    Guthrie RM
    Cardiology; 2010; 117(3):216-8. PubMed ID: 21160183
    [No Abstract]   [Full Text] [Related]  

  • 6. [The ONTARGET trial].
    Verdecchia P; Terrosu P
    G Ital Cardiol (Rome); 2009 Feb; 10(2):67-72. PubMed ID: 19348142
    [No Abstract]   [Full Text] [Related]  

  • 7. [Double blockade of the renin-angiotensin system (RAS): what has the ONTARGET study taught us?].
    Del Vecchio L
    G Ital Nefrol; 2008; 25(6):609. PubMed ID: 19048549
    [No Abstract]   [Full Text] [Related]  

  • 8. Focus on the ONTARGET results.
    Elliott HL
    J Hypertens Suppl; 2009 Jun; 27(2):S8-S10. PubMed ID: 19491625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
    Tobe SW; Clase CM; Gao P; McQueen M; Grosshennig A; Wang X; Teo KK; Yusuf S; Mann JF;
    Circulation; 2011 Mar; 123(10):1098-107. PubMed ID: 21357827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dual blockade of the renin-angiotensin system in hypertensive treatment: yes].
    Middeke M
    Dtsch Med Wochenschr; 2012 Nov; 137(48):2498. PubMed ID: 23168983
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?
    Volpe M; Danser AH; Menard J; Waeber B; Mueller DN; Maggioni AP; Ruilope LM
    J Hypertens; 2012 Apr; 30(4):647-54. PubMed ID: 22278139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new dawn in cardiovascular protection: total cardiovascular risk: rigorous treatment of risk factors. Introduction.
    Ritz E; Dahlöf B
    Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S1-2. PubMed ID: 18580859
    [No Abstract]   [Full Text] [Related]  

  • 13. Proteinuria: Is the ONTARGET renal substudy actually off target?
    Ruggenenti P; Remuzzi G
    Nat Rev Nephrol; 2009 Aug; 5(8):436-7. PubMed ID: 19639016
    [No Abstract]   [Full Text] [Related]  

  • 14. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies.
    Anderson C; Teo K; Gao P; Arima H; Dans A; Unger T; Commerford P; Dyal L; Schumacher H; Pogue J; Paolasso E; Holwerda N; Chazova I; Binbrek A; Young J; Yusuf S;
    Lancet Neurol; 2011 Jan; 10(1):43-53. PubMed ID: 20980201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease.
    Pichler RH; de Boer IH
    Curr Diab Rep; 2010 Aug; 10(4):297-305. PubMed ID: 20532701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular protection: a breakthrough for high-risk patients?
    Ferrari R
    J Hypertens Suppl; 2009 Jul; 27(5):S37-40. PubMed ID: 19587554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is therapy of people with chronic kidney disease ONTARGET?
    Mann JF; Tobe S; Teo KK; Yusuf S
    Nephrol Dial Transplant; 2010 Jan; 25(1):42-4. PubMed ID: 19854846
    [No Abstract]   [Full Text] [Related]  

  • 18. ONTARGET should not be over interpreted.
    Abutaleb N
    Nephrol Dial Transplant; 2010 Jan; 25(1):44-7. PubMed ID: 19934088
    [No Abstract]   [Full Text] [Related]  

  • 19. Is there room for dual blockade of the renin-angiotensin-aldosterone system?
    Hollenberg NK
    J Hypertens; 2012 Apr; 30(4):671-2. PubMed ID: 22418900
    [No Abstract]   [Full Text] [Related]  

  • 20. Nondipping and cardiovascular risk after morning renin-angiotensin blockade.
    Portaluppi F; Smolensky M; Ayala DE; Hermida RC
    Hypertension; 2013 Feb; 61(2):e15. PubMed ID: 23248148
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.